Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 7Sarcoma 6Gliosarcoma 6Glioblastoma 6Multiple Myeloma 5Hematologic Neoplasms 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Rhabdomyosarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Radiotherapy 4Ifosfamide 4Doxorubicin 4Sorafenib 3Etoposide 3cixutumumab 2Vincristine 2Neoadjuvant Therapy 2Epirubicin 2Dactinomycin 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Carboplatin 2trebananib 1temsirolimus 1romidepsin 1Temozolomide 1Specimen Handling 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Imatinib Mesylate 1HhAntag691 1Filgrastim 1Diathermy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemangiosarcoma × Sirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡